Is Pessimism Warranted for These 3 Most Hated Biotech Stocks?
Short-sellers have dog-piled into these three biotech companies. Is their pessimism warranted or have emotions gotten the better of investors?
Could New Competition Create the Next Wave of Stock Losses for This Biotech?
Many think Amarin's initial struggles with Vascepa are normal, and that all bad news is priced into the stock. But with new competition rising, investors might want to buckle up for a Spectrum-like ride.